Zusammenfassung
Mukoviszidose (zystische Fibrose, „cystic fibrosis“ [CF]) ist die häufigste autosomal-rezessiv vererbte Multisystemerkrankung mit fatalem Verlauf. Sie wird durch Mutationen im Cystic-fibrosis-transmembrane-conductance-regulator-Gen (CFTR) verursacht, die zu einer unzureichenden Funktion des Chloridkanals CFTR führen. Infolge dessen kommt es durch unzureichende Hydratisierung des epithelialen Flüssigkeitsfilms zu einer Retention zähen Sekrets in etlichen lebenswichtigen Organen, vor allem in Lunge und Atemwegen, Pankreas, Leber und Gallengängen sowie dem Darm. Dadurch kommt es zu Inflammation und Infektion, Fibrose und progredienter Organdestruktion. Die Mortalität wird im Wesentlichen durch die respiratorische und ventilatorische Insuffizienz bedingt. In den gerade einmal 30 Jahren, die seit der molekularen Charakterisierung des CF-verursachenden CFTR-Basisdefekts vergangen sind, hat sich die Langzeitprognose der betroffenen Patienten enorm verbessert. Diese Prognoseverbesserung ist einerseits auf eine kooperative, sehr aktive und gut vernetzte internationale CF-Forschungsgemeinschaft zurückzuführen, andererseits auf eine standardisierte Behandlung durch ein interdisziplinäres und multiprofessionelles klinisches CF-Team, das die dadurch erfreulicherweise in zahlreichen Aspekten der CF-Therapie vorhandene Evidenz konsequent und gemeinsam mit dem Patienten in Behandlungsstandards umsetzt. Der vorliegende narrative Übersichtsbeitrag zeigt die Evidenz in ausgewählten Bereichen der CF-Therapie auf und würdigt hierbei insbesondere die jüngste Entwicklung der hocheffektiven CFTR-Modulator-Therapie, die in naher Zukunft voraussichtlich etwa 90 % der Betroffenen zur Verfügung stehen wird und die die CF durch ihren Einfluss auf die Pathophysiologie und den Langzeitverlauf in eine gut behandelbare chronische Erkrankung der Inneren Medizin transformieren wird.
Abstract
Mucoviscidosis (cystic fibrosis [CF]) is the most common autosomal recessive inherited multisystem disease with fatal outcome. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which lead to a dysfunctional chloride channel and a defective CFTR protein. As a consequence, retention of insufficiently hydrated mucus affects multiple essential organs, mainly the lungs and airways, pancreas, liver, biliary tract and intestines. This leads to inflammation and infection, fibrosis and progressive tissue destruction. Respiratory failure is the major cause of mortality; however, in the no more than 30 years since the molecular characterization of the basic CFTR defect causing CF, tremendous success has been made with respect to the long-term prognosis of people with CF. This improvement in the prognosis was achieved by the cooperative spirit and networking of the very active and international CF research community and by establishing a multidisciplinary clinical CF team that implements the existing evidence in various aspects of standardized care together with the CF patient. This narrative review article presents the evidence in selected aspects of CF treatment, with special consideration of the most recent development of highly effective CFTR modulator treatment. This treatment will soon become available for more than 90% of the global CF patients and transform the pathophysiology as well as the course of disease towards a treatable chronic condition in internal medicine.
Abbreviations
- ABPA:
-
Allergische bronchopulmonale Aspergillose
- BAL:
-
Bronchoalveoläre Lavage
- BMI:
-
Body-Mass-Index
- CF:
-
„Cystic fibrosis“ (zystische Fibrose, Mukoviszidose)
- CFF:
-
Cystic Fibrosis Foundation
- CFQ‑R:
-
Cystic Fibrosis Questionnaire Revised
- CFTR:
-
„Cystic fibrosis transmembrane conductance regulator“
- ECFS:
-
European Cystic Fibrosis Society
- EKG:
-
Elektrokardiogramm
- EMA:
-
European Medicines Agency
- FDA:
-
US Food and Drug Administration
- FEV1 :
-
„Forced expiratory volume in 1 s“ (exspiratorische Einsekundenkapazität)
- GKV:
-
Gesetzliche Krankenversicherung
- LCI:
-
Lung Clearance Index
- MF:
-
Minimalfunktion
- NTM:
-
Nichttuberkulöse Mykobakterien
- PA:
-
Pseudomonas aeruginosa
- PEP:
-
„Positive expiratory pressure“
- RF:
-
Restfunktion
- rhDNase:
-
Rekombinante humane DNase
Literatur
Adjemian J, Olivier KN, Prevots DR (2018) Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010–2014. Ann Am Thorac Soc 15:817–826
Ahmed MI, Mukherjee S (2018) Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011581.pub3
Amin R, Jahnke N, Waters V (2020) Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009249.pub5
Andrejak C, Nielsen R, Thomsen VO et al (2013) Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 68:256–262
Balazs A, Mall MA (2019) Mucus obstruction and inflammation in early cystic fibrosis lung disease: emerging role of the IL‑1 signaling pathway. Pediatr Pulmonol 54(Suppl 3):S5–S12
Balfour-Lynn IM, Welch K, Smith S (2019) Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001915.pub6
Bell SC, Mall MA, Gutierrez H et al (2020) The future of cystic fibrosis care: a global perspective. Lancet Respir Med 8:65–124
Bhatt J, Jahnke N, Smyth AR (2019) Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002009.pub6
Binder AM, Adjemian J, Olivier KN et al (2013) Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 188:807–812
Blasi F, Elborn JS, Palange P (2019) Adults with cystic fibrosis and pulmonologists: new training needed to recruit future specialists. Eur Respir J 53:1802209
Brode SK, Campitelli MA, Kwong JC et al (2017) The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J 50:1700037
Burkhart M, Nährlich L (2020) Zahlen, Daten & Fakten für Patienten & Angehörige 2020 – Daten aus dem Deutschen Mukoviszidose-Register. Mukoviszidose e. V. & Mukoviszidose Institut gGmbH, Bonn
Calella P, Valerio G, Thomas M et al (2018) Association between body composition and pulmonary function in children and young people with cystic fibrosis. Nutrition 48:73–76
Castellani C, Conway S, Smyth AR et al (2014) Standards of care for cystic fibrosis ten years later. J Cyst Fibros 13(Suppl 1):S1–S2
Castellani C, Duff AJA, Bell SC et al (2018) ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 17:153–178
Cogen JD, Onchiri F, Emerson J et al (2018) Chronic azithromycin use in cystic fibrosis and risk of treatment-emergent respiratory pathogens. Ann Am Thorac Soc 15:702–709
Conway S, Balfour-Lynn IM, De Rijcke K et al (2014) European cystic fibrosis society standards of care: framework for the cystic fibrosis centre. J Cyst Fibros 13(Suppl 1):S3–S22
Coolen N, Morand P, Martin C et al (2015) Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. J Cyst Fibros 14:594–599
Cystic Fibrosis Foundation [CFF]. Drug development pipeline. https://www.cff.org/trials/pipeline. Zugegriffen: 27.09.2020
Davies J, Sheridan H, Bell N et al (2013) Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 1:630–638
De Vries JJ, Chang AB, Bonifant CM et al (2018) Vitamin A and beta (beta)-carotene supplementation for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006751.pub5
Dentice R, Elkins M (2016) Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007923.pub4
Dittrich AM (2017) Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : prevention concepts. Internist 58:1133–1141
Elborn JS (2016) Cystic fibrosis. Lancet 388:2519–2531
Elborn JS (2013) Cystic fibrosis. In: Gibson J, Loddenkemper R, Sibille Y, Lundbäck B (Hrsg) The European lung white book: respiratory health and disease in Europe. European Respiratory Society, Lausanne, S 160–175
Elborn JS, Bell SC, Madge SL et al (2016) Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. Eur Respir J 47:420–428
Elkins M, Dentice R (2020) Timing of hypertonic saline inhalation for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008816.pub4
Eschenhagen P, Schwarz C (2019) Patients with cystic fibrosis become adults : Treatment hopes and disappointments. Internist 60:98–108
Ferguson JH, Chang AB (2014) Vitamin D supplementation for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007298.pub4
Frost F, Shaw M, Nazareth D (2019) Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013079.pub2
Frost FJ, Nazareth DS, Charman SC et al (2019) Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens: a cohort study using national registry data. Ann Am Thorac Soc 16:1375–1382
Goss CH, Sykes J, Stanojevic S et al (2018) Comparison of nutrition and lung function outcomes in patients with cystic fibrosis living in Canada and the United States. Am J Respir Crit Care Med 197:768–775
Griese M, Costa S, Linnemann RW et al (2020) Safety and efficacy of Elexacaftor/Tezacaftor/Ivacaftor for >/= 24 weeks in people with CF and >/= 1 F508del allele: interim results of an open-label phase three clinical trial. Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.202008-3176LE
Heijerman HGM, Mckone EF, Downey DG et al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394:1940–1948
Hewer SCL, Smyth AR, Brown M et al (2020) Intravenous versus oral antibiotics for eradication of pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respir Med 8:975–986
Hoffmann N, Lee B, Hentzer M et al (2007) Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(−/−) mice. Antimicrob Agents Chemother 51:3677–3687
International Physiotherapy Group for Cystic Fibrosis [IPG/CF]. Physiotherapy for people with Cystic Fibrosis: from infant to adult. https://www.cfww.org/docs/ipg-cf/bluebook/bluebooklet2009websiteversion.pdf. Zugegriffen: 03.11.2020
Jagannath VA, Thaker V, Chang AB et al (2020) Vitamin K supplementation for cystic fibrosis. Cochrane Database Syst Rev 6:CD8482
Kerem B, Rommens JM, Buchanan JA et al (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073–1080
Kerem E, Viviani L, Zolin A et al (2014) Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J 43:125–133
Konstan MW, Mckone EF, Moss RB et al (2017) Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med 5:107–118
Lands LC, Stanojevic S (2019) Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001505.pub5
Langton Hewer SC, Smyth AR (2017) Antibiotic strategies for eradicating pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004197.pub5
Lord R, Jones AM, Horsley A (2020) Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009529.pub4
Mcilwaine M, Button B, Dwan K (2015) Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003147.pub4
Middleton PG, Mall MA, Drevinek P et al (2019) Elexacaftor-tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381:1809–1819
Milla CE (2004) Association of nutritional status and pulmonary function in children with cystic fibrosis. Curr Opin Pulm Med 10:505–509
Mogayzel PJ Jr., Naureckas ET, Robinson KA et al (2013) Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187:680–689
Naehrlich L, Burkhart M, Wosniok J (2019) Deutsches Mukoviszidose-Register – Berichtsband 2018. Mukoviszidose Institut, Bonn
Nevitt SJ, Thornton J, Murray CS et al (2020) Inhaled mannitol for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008649.pub3
Nichols DP, Odem-Davis K, Cogen JD et al (2020) Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis. Am J Respir Crit Care Med 201:430–437
Okebukola PO, Kansra S, Barrett J (2020) Vitamin E supplementation in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd009422.pub4
Radtke T, Nolan SJ, Hebestreit H et al (2015) Physical exercise training for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002768.pub3
Ramalho AS, Furstova E, Vonk AM et al (2020) Correction of CFTR function in intestinal organoids to guide treatment of Cystic Fibrosis. Eur Respir J. https://doi.org/10.1183/13993003.02426-2019
Ramsey BW, Davies J, Mcelvaney NG et al (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663–1672
Ratjen F, Davis SD, Stanojevic S et al (2019) Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 7:802–809
Ratjen F, Hug C, Marigowda G et al (2017) Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med 5:557–567
Regan KH, Bhatt J (2019) Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009876.pub4
Renna M, Schaffner C, Brown K et al (2011) Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 121:3554–3563
Reynaud Q, Bricca R, Cavalli Z et al (2020) Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: a meta-analysis. Pediatr Pulmonol 55:2653–2661
Riordan JR, Rommens JM, Kerem B et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073
Rommens JM, Iannuzzi MC, Kerem B et al (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059–1065
Rowe SM, Daines C, Ringshausen FC et al (2017) Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med 377:2024–2035
Saiman L, Anstead M, Mayer-Hamblett N et al (2010) Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303:1707–1715
Schogler A, Kopf BS, Edwards MR et al (2015) Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 45:428–439
Schwarz C, Schulte-Hubbert B, Bend J et al (2018) CF lung disease—a German S3 guideline: module 2: diagnostics and treatment in chronic infection with Pseudomonas aeruginosa. Pneumologie 72:347–392
Singh SB, Mclearn-Montz AJ, Milavetz F et al (2019) Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor. Pediatr Pulmonol 54:1200–1208
Somayaji R, Parkins MD, Shah A et al (2019) Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review. J Cyst Fibros 18:236–243
Southern KW, Barker PM, Solis-Moya A et al (2012) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002203.pub4
Stahl M, Wielputz MO, Ricklefs I et al (2019) Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. Am J Respir Crit Care Med 199:1238–1248
Taylor-Cousar JL, Munck A, Mckone EF et al (2017) Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 377:2013–2023
Tiddens HA, De Boeck K, Clancy JP et al (2015) Open label study of inhaled aztreonam for pseudomonas eradication in children with cystic fibrosis: the ALPINE study. J Cyst Fibros 14:111–119
Tummler B (2020) Progress in understanding the molecular pathology and microbiology of cystic fibrosis. Lancet Respir Med 8:8–10
Food US, Administration D (2019) FDA approves new breakthrough therapy for cystic fibrosis
Van Mourik P, Beekman JM, Van Der Ent CK (2019) Intestinal organoids to model cystic fibrosis. Eur Respir J 54:1802379
Volkova N, Moy K, Evans J et al (2019) Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros 19:68–79
Wainwright CE, Elborn JS, Ramsey BW et al (2015) Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220–231
Wark P, Mcdonald VM (2018) Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001506.pub4
Warnock L, Gates A (2015) Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001401.pub2
Waters V, Ratjen F (2020) Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010004.pub5
Waters V, Stanojevic S, Atenafu EG et al (2012) Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 40:61–66
Waters VJ, Kidd TJ, Canton R et al (2019) Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections. Clin Infect Dis 69:1812–1816
Wilson LM, Morrison L, Robinson KA (2019) Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011231.pub2
Yang C, Montgomery M (2018) Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001127.pub4
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
F. C. Ringshausen bzw. seine Institution hat in den letzten 3 Jahren Forschungsförderung von Bayer, Chiesi, InfectoPharm, Insmed, Grifols, Novartis und Polyphor, Entgelte für die Teilnahme an klinischen Studien von Boehringer Ingelheim, Celtaxsys, Corbus, Insmed, Novartis, Parion Sciences, Polyphor, Vertex und Zambon und finanzielle Unterstützung für die Durchführung von Patienteninformations- und Fortbildungsveranstaltungen von APOSAN, Bayer, Chiesi, InfectoPharm, Insmed, MSD, Novartis, PARI und Vertex erhalten. Darüber hinaus hat F.C. Ringshausen Honorare für Beratungstätigkeiten und Vorträge von AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, Grifols, Insmed, Novartis, Parion Sciences und Zambon erhalten. T. Hellmuth hat eine Forschungsförderung durch das Mukoviszidose Institut gGmbH, Bonn, den Forschungs- und Entwicklungsbereich von Mukoviszidose e. V., erhalten. A.-M. Dittrich bzw. ihre Institution hat in den letzten 3 Jahren Forschungsförderung von Vertex erhalten.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
H. Haller, Hannover
F.C. Ringshausen und A.-M. Dittrich sind Mitglieder des Deutschen Zentrums für Lungenforschung (DZL), Hannover, Deutschland.
Rights and permissions
About this article
Cite this article
Ringshausen, F.C., Hellmuth, T. & Dittrich, A. Was ist gesichert in der Therapie der Mukoviszidose?. Internist 61, 1212–1229 (2020). https://doi.org/10.1007/s00108-020-00896-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-020-00896-9
Schlüsselwörter
- „Cystic fibrosis transmembrane conductance regulator“ (CFTR)
- Evidenzbasierte Medizin
- Entzündungshemmer
- Antibiotika
- CFTR-Modulatoren